News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agilent Technologies, Inc. (Santa Clara, California) (A) Names Expression Analysis, Inc. as Certified Service Provider for Target Enrichment in Next-Generation Sequencing


8/8/2011 11:05:31 AM

SANTA CLARA, Calif., and DURHAM, N.C., Aug. 8, 2011 – Agilent Technologies Inc. (NYSE: A) and Expression Analysis Inc. today announced that Expression Analysis has achieved Certified Service Provider status for the Agilent SureSelect Target Enrichment System.

SureSelect has been shown to greatly increase the speed and cost-efficiency of next-generation sequencing by enabling researchers to focus experiments on genomic regions of interest rather than sequencing the entire genome. Since it was introduced in 2009, SureSelect has been instrumental in more than 100 published studies covering research into a wide range of heritable disorders and complex diseases.

“We have added the SureSelect platform in response to significant client demand,” said Steve McPhail, president and CEO of Expression Analysis.

“Responding to client requirements has been a cornerstone to our success. This platform complements our current technologies and will allow us to meet client demands on many fronts.”

“We’re very pleased to welcome Expression Analysis into the SureSelect service provider community, as they’ve demonstrated considerable skill to become a leading provider of genomic services to researchers,” said Fred P. Ernani, Ph.D., Agilent marketing director, SureSelect NGSplatform.

To achieve Certified Service Provider status, Expression Analysis participated in comprehensive on-site training and then passed a rigorous set of requirements to demonstrate expertise and skill.

There are now more than 20 products in the SureSelect portfolio, with many more in development. SureSelect products are available for enrichment of target sizes ranging from smaller than 200 Kb to more than 50 Mb in a single tube. The SureSelect workflow can be fully automated with Agilent NGS Workstation, and sample throughput can be increased by multiplexing with 96 indexes. SureSelect is compatible with major NGS platforms, such as Illumina, SOLiD and 454. Users of Agilent’s eArray design tool can improve the efficiency of their research by easily designing custom products to target any genomic regions of interest, all in a single tube. SureSelect also allows customization of catalog kits with the addition of custom content.

About Expression Analysis

Expression Analysis (www.ExpressionAnalysis.com) provides whole genome to focused set gene expression and genotyping assays along with DNA sequencings services, sequence enrichment technologies and bioinformatics support. Platforms utilized include Agilent SureSelect, Affymetrix GeneChip and GeneTitan, Fluidigm’s Biomark and Access Array Systems, Illumina BeadChip and Genome Analyzer, RainDance Technologies RDT 1000 and Pacific Biosciences PacBio RS. Expression Analysis offers solutions for challenging specimens such as whole blood and FFPE tissues, as well as nucleic acid isolation and data analysis services. EA’s quality system follows CLSI guidelines and its CLIA-registered laboratory supports GLP compliance.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,500 employees serve customers in more than 100 countries. Agilent had net revenues of $5.4 billion in fiscal 2010. Information about Agilent is available at www.agilent.com.

Louise Muttram

Account Manager

dna medical communications

Fox Court, 14 Grays Inn Road

London, WC1X 8WS

United Kingdom

T:+44 (0)20 7067 0216

F:+44 (0)844 826 8317

LMuttram@dnamedcomms.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES